NovaBay Pharmaceuticals, Inc. (NYSE:NBY) is set to post its quarterly earnings results after the market closes on Wednesday, November 8th. Analysts expect NovaBay Pharmaceuticals to post earnings of ($0.07) per share for the quarter.

NovaBay Pharmaceuticals (NYSE:NBY) last announced its earnings results on Thursday, August 10th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.01. NovaBay Pharmaceuticals had a negative return on equity of 184.30% and a negative net margin of 42.16%. The company had revenue of $4.12 million for the quarter, compared to the consensus estimate of $4.57 million. On average, analysts expect NovaBay Pharmaceuticals to post $-0.47 EPS for the current fiscal year and $-0.11 EPS for the next fiscal year.

NovaBay Pharmaceuticals, Inc. (NYSE NBY) opened at 4.45 on Wednesday. NovaBay Pharmaceuticals, Inc. has a 52 week low of $2.25 and a 52 week high of $5.09. The stock’s market capitalization is $68.13 million. The firm has a 50 day moving average price of $4.46 and a 200 day moving average price of $3.85.

Several equities analysts have recently commented on the company. Zacks Investment Research raised NovaBay Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.00 target price for the company in a report on Thursday, September 21st. HC Wainwright set a $6.00 target price on NovaBay Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 11th. Maxim Group reaffirmed a “hold” rating on shares of NovaBay Pharmaceuticals in a report on Friday, August 11th. Finally, Roth Capital set a $5.00 target price on NovaBay Pharmaceuticals and gave the company a “buy” rating in a report on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $6.40.

COPYRIGHT VIOLATION NOTICE: “NovaBay Pharmaceuticals, Inc. (NBY) Scheduled to Post Earnings on Wednesday” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.

Receive News & Ratings for NovaBay Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.